Circulating α4β7⁺ Memory T Cells in Pediatric IBD Patients Express a Polyclonal T Cell Receptor Repertoire

References

• Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut. 2019;68:1688–1700. doi:10.1136/gutjnl-2018-317977
   PubMed Web of Science ®Google Scholar
• Lamb CA, O’Byrne S, Keir ME, Butcher EC. Gut-selective integrin-targeted therapies for inflammatory bowel disease. J Crohns Colitis. 2018;12:S653–S668. doi:10.1093/ecco-jcc/jjy060
   PubMed Web of Science ®Google Scholar
• Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005;64:1336–1342. doi:10.1212/01.WNL.0000158329.30470.D0
   PubMed Web of Science ®Google Scholar
• Habtezion A, Nguyen LP, Hadeiba H, Butcher EC. Leukocyte trafficking to the small intestine and colon. Gastroenterology. 2016;150:340–354. doi:10.1053/j.gastro.2015.10.046
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–721. doi:10.1056/NEJMoa1215739
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710. doi:10.1056/NEJMoa1215734
   PubMed Web of Science ®Google Scholar
• Kopylov U, Avni-Biron I, Ron Y, et al. Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease-The Israeli real world experience. Dig Liver Dis. 2019;51:68–74. doi:10.1016/j.dld.2018.07.040
   PubMedGoogle Scholar
• Danese S, Sandborn WJ, Colombel J-F, et al. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active crohn’s disease. Gastroenterology. 2019;157:1007–1018 e1007. doi:10.1053/j.gastro.2019.06.038
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Panaccione R, et al. Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis. J Crohns Colitis. 2019;13:172–181. doi:10.1093/ecco-jcc/jjy149
   PubMed Web of Science ®Google Scholar
• Villablanca EJ, De Calisto J, Torregrosa Paredes P, et al. Beta7 integrins are required to give rise to intestinal mononuclear phagocytes with tolerogenic potential. Gut. 2014;63:1431–1440. doi:10.1136/gutjnl-2013-305386
   Web of Science ®Google Scholar
• Schippers A, Muschaweck M, Clahsen T, et al. Beta7-Integrin exacerbates experimental DSS-induced colitis in mice by directing inflammatory monocytes into the colon. Mucosal Immunol. 2016;9:527–538. doi:10.1038/mi.2015.82
   PubMed Web of Science ®Google Scholar
• Zeissig S, Rosati E, Dowds CM, et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. 2019;68:25–39. doi:10.1136/gutjnl-2018-316023
   PubMed Web of Science ®Google Scholar
• Schleier L, Wiendl M, Heidbreder K, et al. Non-classical monocyte homing to the gut via alpha4beta7 integrin mediates macrophage-dependent intestinal wound healing. Gut. 2019. doi:10.1136/gutjnl-2018-316772
   Web of Science ®Google Scholar
• Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol. 2004;4:123–132. doi:10.1038/nri1292
   PubMed Web of Science ®Google Scholar
• Nielsen SCA, Boyd SD. Human adaptive immune receptor repertoire analysis-past, present, and future. Immunol Rev. 2018;284:9–23. doi:10.1111/imr.12667
   PubMed Web of Science ®Google Scholar
• Lossius A, Johansen JN, Vartdal F, Holmoy T. High-throughput sequencing of immune repertoires in multiple sclerosis. Ann Clin Transl Neurol. 2016;3:295–306. doi:10.1002/acn3.295
   Web of Science ®Google Scholar
• Henderson LA, Volpi S, Frugoni F, et al. Next-generation sequencing reveals restriction and clonotypic expansion of treg cells in juvenile idiopathic arthritis. Arthritis Rheum. 2016;68:1758–1768. doi:10.1002/art.39606
   PubMed Web of Science ®Google Scholar
• Harden JL, Hamm D, Gulati N, Lowes MA, Krueger JG. Deep sequencing of the T-cell receptor repertoire demonstrates polyclonal T-cell infiltrates in psoriasis. F1000Res. 2015;4:460. doi:10.12688/f1000research.6756.1
   PubMedGoogle Scholar
• Chapman CG, Yamaguchi R, Tamura K, et al. Characterization of T-cell receptor repertoire in inflamed tissues of patients with crohn’s disease through deep sequencing. Inflamm Bowel Dis. 2016;22:1275–1285. doi:10.1097/MIB.0000000000000752
   Web of Science ®Google Scholar
• Doorenspleet ME, Westera L, Peters CP, et al. Profoundly expanded T-cell clones in the inflamed and uninflamed intestine of patients with crohn’s disease. J Crohns Colitis. 2017;11:831–839. doi:10.1093/ecco-jcc/jjx012
   Web of Science ®Google Scholar
• Allez M, Auzolle C, Ngollo M, et al. T cell clonal expansions in ileal Crohn’s disease are associated with smoking behaviour and postoperative recurrence. Gut. 2019;68:1961–1970. doi:10.1136/gutjnl-2018-317878
   Web of Science ®Google Scholar
• Gunaltay S, Repsilber D, Helenius G, et al. Oligoclonal T-cell receptor repertoire in colonic biopsies of patients with microscopic colitis and ulcerative colitis. Inflamm Bowel Dis. 2017;23:932–945. doi:10.1097/MIB.0000000000001127
   Web of Science ®Google Scholar
• Saravanarajan K, Douglas AR, Ismail MS, et al. Genomic profiling of intestinal T-cell receptor repertoires in inflammatory bowel disease. Genes Immun. 2020;21:109–118. doi:10.1038/s41435-020-0092-x
   PubMed Web of Science ®Google Scholar
• Werner L, Nunberg MY, Rechavi E, et al. Altered T cell receptor beta repertoire patterns in pediatric ulcerative colitis. Clin Exp Immunol. 2019;196:1–11. doi:10.1111/cei.13247
   Web of Science ®Google Scholar
• Rosati E, Pogorelyy MV, Dowds CM, et al. Identification of disease-associated traits and clonotypes in the T cell receptor repertoire of monozygotic twins affected by inflammatory bowel diseases. J Crohns Colitis. 2020. doi:10.1093/ecco-jcc/jjz210
   Web of Science ®Google Scholar
• Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, Phase 2 trial. Lancet. 2014;384:309–318. doi:10.1016/S0140-6736(14)60661-9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Cyrille M, Hansen MB, et al. Efficacy and safety of abrilumab in a randomized, placebo-controlled trial for moderate-to-severe ulcerative colitis. Gastroenterology. 2019;156:946–957 e918. doi:10.1053/j.gastro.2018.11.035
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of AJM300, an oral antagonist of alpha4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015;149:1775–1783 e1772. doi:10.1053/j.gastro.2015.08.044
   PubMed Web of Science ®Google Scholar
• Ungar B, Kopylov U, Yavzori M, et al. Association of vedolizumab level, anti-drug antibodies, and alpha4 beta7 occupancy with response in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16:697–705 e697. doi:10.1016/j.cgh.2017.11.050
   PubMed Web of Science ®Google Scholar
• Dotan I, Allez M, Danese S, et al. The role of integrins in the pathogenesis of inflammatory bowel disease: approved and investigational anti-integrin therapies. Med Res Rev. 2020;40:245–262. doi:10.1002/med.21601
   PubMed Web of Science ®Google Scholar